Bloomberg News

Clal Biotechnology Climbs Most in Week on Alzheimer’s Drug Trial

January 23, 2012

Jan. 23 (Bloomberg) -- Clal Biotechnology Industries Ltd. advanced the most in a week after a unit’s Phase IIb trial of an Alzheimer’s drug showed intermediate “positive” results.

The shares of the investment company gained as much as 2.3 percent, the biggest intraday increase since Jan. 16, and were 1 percent higher at 21.10 shekels as of 11:24 a.m. in Tel Aviv.

--Editors: Susan Lerner, Shanthy Nambiar

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Steve Ballmer, Power Forward
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus